KORU Medical Systems, Inc. (NASDAQ:KRMD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

KORU Medical Systems, Inc. (NASDAQ:KRMD) has been assigned an average rating of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $7.25.

KRMD has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Tuesday, April 21st. Canaccord Genuity Group reissued a “buy” rating and set a $6.00 price target on shares of KORU Medical Systems in a research report on Friday, March 13th. Wall Street Zen lowered shares of KORU Medical Systems from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, B. Riley Financial upped their price target on shares of KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 13th.

KORU Medical Systems Stock Down 2.0%

Shares of KORU Medical Systems stock traded down $0.08 during trading hours on Friday, hitting $3.90. 147,083 shares of the company’s stock traded hands, compared to its average volume of 141,384. KORU Medical Systems has a twelve month low of $2.63 and a twelve month high of $6.61. The company has a market cap of $179.13 million, a PE ratio of -78.00 and a beta of 0.43. The stock has a 50 day simple moving average of $4.23 and a 200-day simple moving average of $4.84.

KORU Medical Systems (NASDAQ:KRMD) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). The business had revenue of $11.76 million for the quarter, compared to analysts’ expectations of $11.28 million. KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%. As a group, equities research analysts predict that KORU Medical Systems will post -0.03 EPS for the current year.

Hedge Funds Weigh In On KORU Medical Systems

A number of hedge funds have recently bought and sold shares of KRMD. Vivaldi Capital Management LP increased its holdings in KORU Medical Systems by 51.6% in the first quarter. Vivaldi Capital Management LP now owns 29,885 shares of the company’s stock valued at $129,000 after buying an additional 10,172 shares during the last quarter. Renaissance Technologies LLC bought a new position in KORU Medical Systems during the 1st quarter worth approximately $198,000. Arrowstreet Capital Limited Partnership bought a new position in KORU Medical Systems during the 1st quarter worth approximately $79,000. Sei Investments Co. grew its position in shares of KORU Medical Systems by 14.8% in the 1st quarter. Sei Investments Co. now owns 93,772 shares of the company’s stock worth $405,000 after acquiring an additional 12,062 shares in the last quarter. Finally, Hillsdale Investment Management Inc. grew its position in shares of KORU Medical Systems by 3,743.8% in the 1st quarter. Hillsdale Investment Management Inc. now owns 61,500 shares of the company’s stock worth $266,000 after acquiring an additional 59,900 shares in the last quarter. 58.60% of the stock is currently owned by institutional investors and hedge funds.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.